tiprankstipranks
Trending News
More News >
Tenet Healthcare (THC)
NYSE:THC

Tenet Healthcare (THC) AI Stock Analysis

Compare
856 Followers

Top Page

TH

Tenet Healthcare

(NYSE:THC)

77Outperform
Tenet Healthcare's overall stock score reflects its strong financial performance, strategic growth plans, and undervaluation. The key strengths lie in revenue growth, profitability, and effective debt management. However, bearish technical indicators and potential revenue pressures from hospital divestitures and non-recurring Medicaid payments pose challenges.
Positive Factors
Financial Management
Broader demand trends remain strong and Tenet Healthcare Corp is managing expenses, including labor, very well.
Stock Valuation
The stock's valuation is below what is considered a fair value multiple, even in a worst-case political scenario.
Negative Factors
Healthcare Policy Changes
Uncertainty around potential changes in healthcare policy and government spending cuts are weighing on the stock.
Healthcare Regulations
Investors are concerned with the uncertainty surrounding healthcare regulations which could reduce earnings power.

Tenet Healthcare (THC) vs. S&P 500 (SPY)

Tenet Healthcare Business Overview & Revenue Model

Company DescriptionTenet Healthcare Corporation operates as a diversified healthcare services company. The company operates in three segments: Hospital Operations and Other, Ambulatory Care, and Conifer. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive and critical care, and coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics services; outpatient services, including physical therapy; cardiothoracic surgery, complex spinal surgery, neonatal intensive care, and neurosurgery services; quaternary care services in heart and kidney transplants; and limb-salvaging vascular procedure, acute level 1 trauma, intravascular stroke care, minimally invasive cardiac valve replacement, imaging, and telemedicine access services. In addition, it operates ambulatory surgery and urgent care centers, imaging centers, surgical hospitals, off-campus emergency departments, and micro-hospitals; and offers healthcare business process services in the areas of hospital and physician revenue cycle management, patient communications and engagement support, and value-based care solutions to hospitals, health systems, physician practices, employers, and other customers. As of February 09, 2022, the company operated 60 hospitals; and approximately 550 other healthcare facilities, including surgical hospitals, ambulatory surgery centers, urgent care and imaging centers, and other care sites and clinics. Tenet Healthcare Corporation was incorporated in 1975 and is headquartered in Dallas, Texas.
How the Company Makes MoneyTenet Healthcare generates revenue through a combination of patient service revenues from its network of hospitals and outpatient centers, management fees from its surgical facilities, and business solutions services. The company earns income from providing medical services, surgeries, and treatments in its hospitals and ambulatory centers, and it receives payments from patients, insurance companies, and government programs such as Medicare and Medicaid. Tenet's subsidiary, USPI, contributes to earnings by managing surgical facilities, where it charges management fees and shares profits from joint venture partnerships with physicians and health systems. Additionally, Conifer Health Solutions provides revenue cycle management and value-based care services to healthcare providers, generating further revenue streams.

Tenet Healthcare Financial Statement Overview

Summary
Tenet Healthcare exhibits strong financial health with improvements in revenue growth, profitability, and debt management. Although there are fluctuations in EBITDA margins and free cash flow ratios, the focus on reducing debt and enhancing equity is positive. Continued attention to margin expansion and cash flow stability is crucial.
Income Statement
85
Very Positive
Tenet Healthcare has shown a strong revenue growth trend, with revenues increasing from $17.64 billion in 2020 to $20.67 billion in 2024. The gross profit margin is solid, indicating good cost management, while the net profit margin shows a significant improvement in 2024, highlighting enhanced profitability. The EBIT margin also reflects strong operational efficiency. However, EBITDA margin saw a decrease, pointing to potential challenges in maintaining consistent earnings before interest, taxes, depreciation, and amortization.
Balance Sheet
78
Positive
The balance sheet indicates a substantial reduction in total debt by 2024, improving the debt-to-equity ratio significantly. The return on equity (ROE) has improved, demonstrating effective utilization of shareholder's equity to generate profits. The equity ratio is still low, suggesting a higher reliance on liabilities but has improved over the years, indicating a positive trend towards strengthening equity.
Cash Flow
82
Very Positive
Tenet Healthcare's cash flow from operations has been consistently positive, with a solid free cash flow growth in recent years. The operating cash flow to net income ratio is healthy, showcasing efficient cash generation relative to net income. However, free cash flow to net income ratio indicates some variability, suggesting potential challenges in maintaining consistent free cash flow relative to net income.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
20.66B20.55B19.17B19.48B17.64B
Gross Profit
11.86B16.96B15.90B16.16B14.66B
EBIT
5.96B2.51B2.33B2.87B1.99B
EBITDA
6.89B3.39B3.33B3.42B2.43B
Net Income Common Stockholders
3.20B611.00M1.00B1.48B768.00M
Balance SheetCash, Cash Equivalents and Short-Term Investments
3.02B1.23B858.00M2.36B2.45B
Total Assets
28.94B28.31B27.16B27.58B27.11B
Total Debt
92.00M16.21B15.08B15.65B15.72B
Net Debt
-2.93B14.98B14.22B13.28B13.27B
Total Liabilities
20.39B22.80B22.55B23.32B24.22B
Stockholders Equity
4.17B1.61B1.14B1.03B28.00M
Cash FlowFree Cash Flow
1.12B1.62B321.00M910.00M2.87B
Operating Cash Flow
2.05B2.37B1.08B1.57B3.41B
Investing Cash Flow
3.43B-969.00M-808.00M-714.00M-1.61B
Financing Cash Flow
-3.69B-1.03B-1.78B-936.00M385.00M

Tenet Healthcare Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price122.10
Price Trends
50DMA
127.07
Negative
100DMA
130.81
Negative
200DMA
142.64
Negative
Market Momentum
MACD
-2.41
Positive
RSI
47.77
Neutral
STOCH
67.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For THC, the sentiment is Neutral. The current price of 122.1 is below the 20-day moving average (MA) of 124.68, below the 50-day MA of 127.07, and below the 200-day MA of 142.64, indicating a bearish trend. The MACD of -2.41 indicates Positive momentum. The RSI at 47.77 is Neutral, neither overbought nor oversold. The STOCH value of 67.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for THC.

Tenet Healthcare Risk Analysis

Tenet Healthcare disclosed 25 risk factors in its most recent earnings report. Tenet Healthcare reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Tenet Healthcare Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
THTHC
77
Outperform
$11.78B3.84110.75%0.57%440.71%
UHUHS
73
Outperform
$11.43B10.4317.82%0.47%10.82%65.64%
FMFMS
72
Outperform
$14.36B24.383.87%1.83%-0.57%8.25%
HCHCA
70
Outperform
$83.86B15.48-230.22%0.82%7.30%
EHEHC
70
Outperform
$11.45B20.9525.35%0.56%11.21%30.49%
DVDVA
64
Neutral
$11.16B12.99159.08%5.56%45.02%
51
Neutral
$5.32B3.41-40.36%2.89%17.93%2.52%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
THC
Tenet Healthcare
122.10
22.95
23.15%
DVA
DaVita
139.56
1.42
1.03%
FMS
Fresenius Medical Care
24.46
4.16
20.49%
HCA
HCA Healthcare
327.92
18.98
6.14%
EHC
Encompass Health
113.37
30.32
36.51%
UHS
Universal Health
171.68
3.24
1.92%

Tenet Healthcare Earnings Call Summary

Earnings Call Date: Feb 12, 2025 | % Change Since: -12.05% | Next Earnings Date: Apr 29, 2025
Earnings Call Sentiment Neutral
Tenet Healthcare demonstrated strong financial performance and strategic growth in 2024, particularly in its USPI segment and through share repurchases. However, challenges such as the impact of hospital divestitures and non-recurring Medicaid payments present potential headwinds. Overall, the company's results and outlook suggest a balanced approach to managing growth and operational efficiency.
Highlights
Strong Financial Performance
Tenet Healthcare reported operating revenues of $20.7 billion and consolidated adjusted EBITDA of $4 billion for 2024, representing a 13% growth over 2023.
Improved EBITDA Margin
Full-year adjusted EBITDA margin improved by over 200 basis points to 19.3% compared to the previous year.
USPI Segment Growth
USPI generated $1.81 billion in adjusted EBITDA in 2024, marking a 17% growth over 2023, with adjusted EBITDA margins of 42.1%.
Hospital Segment Performance
Despite the sale of 14 hospitals, the Hospital segment achieved $2.185 billion of adjusted EBITDA in 2024, a 9% increase over the prior year.
Significant Share Repurchase
Tenet returned capital to shareholders by repurchasing approximately 14% of its outstanding shares for $1.12 billion since the fourth quarter of 2022.
Deleveraged Balance Sheet
Year-end leverage ratio improved to 2.5x EBITDA, supported by hospital divestitures and strong operational performance.
Lowlights
Hospital Divestitures
The sale of 14 hospitals resulted in a reduction of $114 million in adjusted EBITDA from facilities that will not recur in 2025.
Supplemental Medicaid Payment Challenges
Tenet received $74 million in out-of-period supplemental Medicaid payments in 2024, which will not recur in 2025, indicating potential future revenue pressures.
Supply Cost Increase
Supply costs increased to 18.3% of revenue, reflecting higher acuity procedures but posing a challenge to cost management.
Company Guidance
During Tenet Healthcare's fourth-quarter 2024 earnings call, the company provided guidance for 2025, projecting full-year adjusted EBITDA between $3.975 billion and $4.175 billion, indicating a 7% growth at the midpoint on a normalized basis. Specifically, they anticipate USPI's adjusted EBITDA growth of approximately 8.5%, driven by 3% to 6% same-facility revenue growth, and the addition of 10 to 12 de novo centers. The Hospital segment is expected to see a 5.7% growth in adjusted EBITDA, with 2% to 3% growth in adjusted admissions. The company also plans to invest around $250 million annually in ambulatory M&A. Tenet aims for net operating revenues between $20.6 billion and $21.0 billion for the year, reflecting robust operational efficiencies and disciplined cost management. Additionally, they expect to have substantial free cash flow, projected between $1.8 billion and $2.05 billion, after capital expenditures of $700 million to $800 million.

Tenet Healthcare Corporate Events

Executive/Board Changes
Tenet Healthcare Updates CEO Compensation Agreement
Neutral
Jan 24, 2025

On January 23, 2025, Tenet Healthcare Corporation entered into an amended employment agreement with its CEO, Saumya Sutaria. The agreement outlines his compensation, including a base salary of $1.5 million and an annual incentive plan, as well as stock incentives valued at $18 million. The contract includes provisions for termination benefits and performance-based vesting of stock units, impacting the company’s leadership stability and aligning executive interests with long-term performance goals.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.